Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT06633042
PHASE1
The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD
Sponsor: Bioray Laboratories
View on ClinicalTrials.gov
Summary
This is an open label, Multi-center,dose-escalation study in up to 18 participants with refractory NMOSD. This study aims to evaluate the safety and efficacy of universal CAR-T Cells targeting BCMA in the Treatment of refractory NMOSD.
Official title: The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disease
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2024-11-25
Completion Date
2025-12-12
Last Updated
2024-11-12
Healthy Volunteers
No
Conditions
Interventions
DRUG
Universal BCMA-CD19 CART
1.0-4.0×10\^6 CAR-T cells/kg